JP Morgan Maintains Overweight on Synovus Finl, Lowers Price Target to $46

JP Morgan analyst Steven Alexopoulos maintains Synovus Finl (NYSE:SNV) with a Overweight and lowers the price target from $60 to $46.

JP Morgan analyst Steven Alexopoulos maintains Synovus Finl (NYSE:SNV) with a Overweight and lowers the price target from $60 to $46.

Total
0
Shares
Related Posts
Read More

Novartis and Medicines for Malaria Venture Announce Decision to Move to Phase 3 Study for Novel Ganaplacide/lumefantrine-SDF Combination in Adults and Children With Malaria

As the threat of resistance to current malaria treatments grows1,2, Novartis and MMV announce the decision to progress ganaplacide/lumefantrine- solid dispersion formulation (SDF) into Phase 3 development for the treatment of patients with acute uncomplicated malaria due to Plasmodium falciparum.

NVS